Its losses have been rising in recent years as has its share count -- a notable concern for investors. 10 stocks we like ...
TipRanks on MSN
Roche Exercises Option with Recursion Pharmaceuticals
An announcement from Recursion Pharmaceuticals ( ($RXRX) ) is now available. On October 29, 2025, Recursion Pharmaceuticals announced that Roche ...
Recursion Pharmaceuticals developed a promising artificial intelligence (AI) platform for drug discovery and development. The company's clinical-stage pipeline is just the tip of the iceberg of its ...
Well over a decade has passed since the release of Mojang 's monumental sandbox game Minecraft, with countless mods dropping ...
Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today it will provide business updates and report its third quarter 2025 ...
In the latest close session, Recursion Pharmaceuticals (RXRX) was down 5.42% at $5.23. The stock fell short of the S&P 500, which registered a loss of 0.38% for the day. Meanwhile, the Dow experienced ...
The Jakarta Persistence API (JPA) is a specification that defines a standardized framework for data persistence. Persistence is the fundamental mechanism for saving and retrieving data over time. In ...
Recursion Pharmaceuticals (RXRX) shares ended the last trading session 8.2% higher at $5.52. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the ...
Recursion Pharmaceuticals (NASDAQ:RXRX), a $2.3 billion market cap biotech company currently trading at $5.31, saw Chief Executive Officer Christopher Gibson sell 100,000 shares of Class A Common ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback